<SEC-DOCUMENT>0001683168-17-001069.txt : 20170502
<SEC-HEADER>0001683168-17-001069.hdr.sgml : 20170502
<ACCEPTANCE-DATETIME>20170502080733
ACCESSION NUMBER:		0001683168-17-001069
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170501
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170502
DATE AS OF CHANGE:		20170502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PharmaCyte Biotech, Inc.
		CENTRAL INDEX KEY:			0001157075
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				621772151
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-68008
		FILM NUMBER:		17802968

	BUSINESS ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653
		BUSINESS PHONE:		(917) 595.2850

	MAIL ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVILEX, INC.
		DATE OF NAME CHANGE:	20090324

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EFOODSAFETY COM INC
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pharmabio_8k-050117.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 3pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
<FONT STYLE="font-size: 12pt"><B>Form 8-K</B></FONT><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Current Report </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May 2, 2017 (May 1, 2017)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B><U>PHARMACYTE
BIOTECH, INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Nevada</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>333-68008</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>62-1772151</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation) </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number) </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.) </FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23046 Avenida de la Carlota, Suite 600</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Laguna Hills, CA</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>92653</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant's telephone number, including
area code: <B>(917) 595-2850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%; text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>N/A </U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Written communications pursuant to Rule 425 under the Securities
Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 3pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 10%"><B>Item 5.02</B></TD>
    <TD STYLE="text-align: left; width: 90%"><B>Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2017, the Board of Directors
(&ldquo;Board&rdquo;) of PharmaCyte Biotech, Inc., a Nevada corporation (&ldquo;Company&rdquo;), appointed Thomas C. K. Yuen (&ldquo;Mr.
Yuen&rdquo;) to the Board to fill a vacancy created by the departure of certain members of the Board in October 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with Mr. Yuen&rsquo;s appointment
to the Board, the Company entered into a letter agreement (&ldquo;Letter Agreement&rdquo;) with Mr. Yuen pursuant to which the
Company agreed to pay Mr. Yuen $12,500 in cash for each calendar quarter of service on the Board and agreed to issue annually:
(i) 250,000 fully-paid, non-assessable shares of the Company&rsquo;s restricted common stock (&ldquo;Shares&rdquo;); and (ii) a
five-year option to purchase 250,000 shares of the Company&rsquo;s restricted common stock (&ldquo;Option&rdquo;) to Mr. Yuen at
an exercise price equal to the fair market value of the Company&rsquo;s common stock on the date of grant. The Shares and the Option
were fully vested on the date of the grants. The Board of Directors approved the initial issuances of the Shares and the Option
on May 1, 2017, and the Option has an exercise price of $0.0734 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Letter
Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Letter Agreement,
a copy of which is filed as Exhibit 10.1 to this Form 8-K and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 7.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attached hereto as Exhibit 99.1 is a copy of the Company&rsquo;s
press release dated May 1, 2017, regarding the appointment of Mr. Yuen to the Company&rsquo;s Board. The information furnished
in this Item 7.01, including Exhibit 99.1, shall not be deemed to be &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 10%"><B>Item 9.01.</B></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 90%"><B>Financial Statements and Exhibits.</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(d) Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="width: 93%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement between the Company and Mr. Yuen dated May 1, 2017.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PharmaCyte Biotech, Inc. press release dated May 2, 2017 (furnished pursuant to Item 7.01).</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: May 2, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PHARMACYTE BIOTECH, INC.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: <U>/s/ Kenneth L. Waggoner</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Kenneth L. Waggoner</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">President and General Counsel</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No.</B></P></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement between the Company and Mr. Yuen dated May 1, 2017.</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PharmaCyte Biotech, Inc. press release dated May 1, 2017 (furnished pursuant to Item 7.01).</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 6%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 82%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 9%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>pharmabio_8k-ex1001.htm
<DESCRIPTION>LETTER AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>VIA EMAIL ONLY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0">May 1, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Thomas C. K. Yuen<BR>
2917 Daimler Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Santa Ana, California 92705</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0"><B>Re:&nbsp;&nbsp;&nbsp;</B>&nbsp;<B><U>Director Offer Letter</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0">Dear Mr. Yuen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">This letter shall constitute an
agreement (&ldquo;<U>Agreement</U>&rdquo;) between you and PharmaCyte Biotech (&ldquo;<U>Company</U>&rdquo;) and contains all the
terms and conditions relating to your service to the Company as a member of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>1. </B>&nbsp;<B><U>Term</U>.</B>
This Agreement will become effective as of May 1, 2017 (&ldquo;<U>Effective Date</U>&rdquo;) and continue until your resignation
or removal, or until your successor is duly elected and qualified. Your position will be subject to re-election each year at the
annual shareholders&rsquo; meeting and, upon re-election, the terms and provisions of this Agreement shall remain in full force
and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>2.</B>&#9;<B><U>Services</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>2.1.</B> &#9;<B><U>Duties</U>.
</B>You shall render services as a member of the Board in accordance with high professional and ethical standards and in accordance
with all applicable laws, rules and regulations pertaining to your performance under this Agreement. You shall use your best efforts
to attend all meetings of the Board called from time to time, either in-person or by telephone. You will serve as member of the
Audit Committee and the Compensation Committee of the Board and shall use your best efforts to attend meetings of each Committee
as required by its members pursuant to the Charter of each Committee or as may be called from time to time. As an independent director,
you may also be required to attend meetings with the other independent directors without the presence of the Company&rsquo;s officers
and non-independent directors. The services described in this Section 2.1 shall hereinafter be referred to as your &ldquo;<U>Duties</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>2.2.</B> &#9;<B><U>Reporting</U>.</B>
While this Agreement is in effect, you shall immediately advise the Company if: (i) you know, have reason to know, or believe,
that you are no longer independent; and (ii) you serve on an audit committee of any other public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>3.</B>&#9;<B><U>Services for
Others</U>.</B> You shall be free to represent or perform services for other persons during the term of this Agreement. You represent,
however, that you do not presently perform and do not intend to perform, during the term of this Agreement, similar duties, consulting,
or other services for companies whose businesses are or would be in any way competitive with the Company (except for companies
previously disclosed by you to the Company in writing). Should you propose to perform similar duties, consulting, or other services
for any such company, you agree to notify the Company in writing in advance (specifying the name of the organization for whom
you propose to perform such services) and to provide information to the Company sufficient to allow it to determine if the performance
of such services would conflict with your duties as a director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>4.</B>&#9;<B><U>Compensation</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>4.1.</B>&#9;<B><U>Cash</U>.</B>
The Company will pay you cash compensation of $12,500 per quarter, payable in advance and pro-rated for periods of less than a
quarter. You shall be reimbursed for reasonable expenses documented and incurred by you in performing your Duties (including travel
expenses for meetings you attend in-person).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>4.2.</B>&#9;<B><U>Equity Grants</U>.</B>
Commencing on the Effective Date and on each anniversary date of the Effective Date, you will be issued annually: (i) 250,000 fully-paid,
non-assessable shares of the Company&rsquo;s restricted common stock (&ldquo;Shares&rdquo;); and (ii) a five-year option to purchase
250,000 shares of the Company&rsquo;s restricted common stock at an exercise price equal to the fair market value of the Company&rsquo;s
common stock on the date of the grant (&ldquo;Option&rdquo;). The Shares and the Option will be fully vested as of the date of
the grant. The Company will issue you a Stock Option Agreement to evidence the Option in the form typically used by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>4.3.</B>&#9;<B><U>Service on
Additional Board Committee</U>.</B> Should you be named to any additional committee of the Board, the Compensation Committee of
the Board will determine any additional compensation, if any, that you will receive for serving on such committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>4.4. &#9;<U>Taxes</U>. </B><FONT STYLE="font-weight: normal">You
are solely responsible for taxes arising out of any compensation paid by the Company to you under this Agreement, and you understand
that you will be issued a U.S. Treasury form 1099 for any compensation paid to you by the Company. The Company will comply with
any tax or withholding obligations as required by applicable law from time to time related to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>5. &#9;<U>D&amp;O Insurance
Policy</U>. </B><FONT STYLE="font-weight: normal">During the term of this Agreement, the Company shall include you as an insured
under its existing director&rsquo;s and officer&rsquo;s insurance policy, with coverage determined annually by the Company and
the Board. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>6.</B>&nbsp;<B><U>No Assignment</U>.</B>
Because of the personal nature of the services to be rendered by you, this Agreement may not be assigned by you without the prior
written consent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>7.</B>&nbsp;<B><U>Confidential
Information; Non-Disclosure</U>.</B> In consideration of your access to the premises of the Company and/or you access to certain
confidential information of the Company, you hereby represent and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>7.1.</B>&#9;<B><U>Definition</U>.</B>
For purposes of this Agreement, the term &ldquo;<U>Confidential Information</U>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>a.</B>&nbsp;Any information
that the Company possesses that has been created, discovered, or developed by or for the Company and that has or could have commercial
value or utility in the business in which the Company is engaged;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>b.</B>&#9;Any information provided
to the Board at or for meetings of the Board and any information relating to proceedings of the Board; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>c.</B>&nbsp;Any information
that is related to the business of the Company and is generally not known by non-Company personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>7.2.&#9;<U>Exclusions</U>.</B>
Notwithstanding the foregoing, the term Confidential Information does not include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>a.</B>&nbsp;Any information
that becomes generally available to the public other than as a result of a breach of this Agreement, or any other agreement requiring
confidentiality between the Company and you;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>b.</B>&nbsp;Information received
from a third party in rightful possession of such information who is not restricted from disclosing such information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>c.</B>&nbsp;Information known
by you prior to receipt of such information from the Company, which prior knowledge can be documented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>7.3.</B>&nbsp;<B><U>Documents</U>.</B>
You agree that, without the express prior written consent of the Company, you will not remove from the Company's premises, any
notes, formulas, programs, data, records, machines, or any other documents or items that in any manner contain or constitute Confidential
Information, nor will you make reproductions or copies of the same. In the event you receive any such documents or items by personal
delivery from any duly designated or authorized personnel of the Company, you shall be deemed to have received the express written
consent of the Company. In the event that you receive any such documents or items, other than through personal delivery as described
in the preceding sentence, you agree to inform the Company promptly of your possession of such documents or items. You shall promptly
return any such documents or items, along with any reproductions or copies to the Company upon the Company's demand, upon termination
of this Agreement, or upon your termination or Resignation, as defined in Section 8, below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 60pt"><B>7.4.</B>&nbsp;<B><U>No Disclosure</U>.</B>
You agree that you will hold in trust and confidence all Confidential Information and will not disclose to others, directly or
indirectly, any Confidential Information or anything relating to such information without the prior written consent of the Company,
except as maybe necessary in the course of your relationship with the Company. You further agree that you will not use any Confidential
Information other than in connection with your service as a member of the Board without the prior written consent of the Company.
The provisions of this Section 7.4 shall survive termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>8.</B>&nbsp;&#9;<B><U>Termination
and Resignation</U>.</B> Your membership on the Company&rsquo;s Board may be terminated for any or no reason except as provided
in the Company&rsquo;s organizational documents or pursuant to applicable law. You may also terminate your membership on the Board
for any or no reason by delivering your written notice of resignation to the Company (&ldquo;<U>Resignation</U>&rdquo;). Such Resignation
shall be effective on the later of the date of its delivery or the date specified in the Resignation. Upon the effective date of
the termination or Resignation, your right to compensation under this Agreement will terminate, subject to the Company's obligations
to pay you any compensation that you have already earned and to reimburse you for approved expenses already incurred in connection
with you performing your Duties as of the effective date of such termination or Resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>9. &#9;<U>Not an Employee</U>.
</B>Nothing in this Agreement shall be construed as a contract of employment/engagement between you and the Company or as a commitment
on the part of the Company to retain you in any capacity, for any period of time or under any specific terms or conditions, or
to continue your service to the Company beyond any period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>10.</B>&#9;<B><U>Governing
Law; Consent to Jurisdiction</U>. </B> All questions with respect to the construction and/or enforcement of this Agreement, and
the rights and obligations of the parties hereunder, shall be determined in accordance with the laws of the State of California
applicable to agreements made and to be performed entirely in the State of California. The parties hereby consent to the jurisdiction
of the courts having jurisdiction over matters arising in California for any proceeding arising out of or relating to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>11.</B>&#9;<B><U>Entire Agreement;
Amendment; Waiver; Counterparts</U>.</B> This Agreement expresses the entire understanding with respect to the subject matter
hereof and supersedes and terminates any prior oral or written agreements with respect to the subject matter hereof. Any term
of this Agreement may be amended and observance of any term of this Agreement may be waived only with the written consent of the
parties hereto. Waiver of any term or condition of this Agreement by any party shall not be construed as a waiver of any subsequent
breach or failure of the same term or condition or waiver of any other term or condition of this Agreement. The failure of any
party at any time to require performance by any other party of any provision of this Agreement shall not affect the right of any
such party to require future performance of such provision or any other provision of this Agreement. This Agreement may be executed
in separate counterparts each of which will be an original and all of which taken together will constitute one and the same agreement,
and may be executed using facsimiles of signatures, and a facsimile of a signature shall be deemed to be the same, and equally
enforceable, as an original of such signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B><I>[Signature page to follow]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">This Agreement has been executed
and delivered by the undersigned and is made effective as of the date set first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sincerely,</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-indent: 0.5in; width: 44%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PharmaCyte Biotech, Inc.</B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-indent: 0.5in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-indent: 0.5in">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:
    </TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">/s/ Kenneth L. Waggoner</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: </TD>
    <TD STYLE="font-size: 10pt; text-align: left">Kenneth L. Waggoner</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: </TD>
    <TD STYLE="text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0.5in; margin-bottom: 0pt; text-align: left">Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">President and General Counsel</P></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in"><B>AGREED AND ACCEPTED</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in"><U>/s/ Thomas C. K. Yuen&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in">Name: Thomas C. K. Yuen</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>pharmabio_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>PharmaCyte
Biotech Appoints Thomas Yuen to Board of Directors</B></FONT><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LAGUNA HILLS, Calif., May 2, 2017 (GLOBE
NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted therapies
for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box<SUP>&reg;</SUP>, today announced
the appointment of Thomas Yuen to its Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Yuen&rsquo;s stellar career is exemplified
by his global entrepreneurial experience and extraordinary leadership. He co-founded Irvine-based AST Research, Inc. (AST) in 1981.
AST was an early pioneer of the computer industry, and the company has been referred to as &ldquo;the flagship of innovation in
the PC era.&rdquo; He served as AST's Co-Chairman and Chief Operating Officer from August 1987 to June 1992. Under his leadership,
AST became a Fortune 500 company in 1991, and its stock was named the &ldquo;Best Performing NASDAQ Stock&rdquo; of that year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Yuen departed AST in 1992 and focused
his efforts on investing in new projects. Mr. Yuen served in various engineering and project management positions with Hughes Aircraft
Company, Sperry Univac and Computer Automation. Later in his career, he became Chairman and CEO of SRS Labs, a world leader in
audio and voice technology. Currently, Mr. Yuen is Chairman and CEO of PrimeGen Biotech, a private cell therapy company he founded
in 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmaCyte&rsquo;s Chief Executive Officer,
Kenneth L. Waggoner, stated, &ldquo;We are extremely honored that Mr. Yuen has agreed to become a member of our Board of Directors.
His widespread business experience at the highest levels around the globe, business acumen and entrepreneurial spirit will be major
assets to PharmaCyte as we strive to take the company to an entirely new level.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Yuen commented, &ldquo;I am very pleased
to become a member of PharmaCyte&rsquo;s Board of Directors. PharmaCyte is a dynamic and exciting company with a transformative
platform technology. There are a multitude of opportunities for growth in cell therapies, and I intend to play a significant role
in helping PharmaCyte achieve its business goals.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Yuen has held numerous director positions.
He served as a Director of AST from 1981 to June 1992. He served as a Director of Valence Technology, Inc., an energy storage company,
from March 1998 to March 2000 and a Director of DTS, Inc., an audio technology company, from April 2012 to July 2013. He has served
as a Director of SRS Labs since January 1994. He is also an Honorary Professor of China Nationality University in Beijing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 1988 and 1991, the Computer Reseller
News Magazine named Mr. Yuen one of the top 25 executives of the computer industry. In 1997, he received the Director of the Year
Award from the Orange County Foundation of Corporate Directors. Mr. Yuen is the recipient of several awards from the University
of California, Irvine (UCI), including the UCI Medal in 1990, the Outstanding Engineering Alumni Award in 1987 and the Distinguished
Alumnus Award in 1986. These accolades will soon culminate in Mr. Yuen receiving the prestigious UCI Extraordinarious Award for
his exemplary career in business and his philanthropic and volunteer activities. As further testament to his outstanding achievements,
Mr. Yuen is the first of UCI&rsquo;s 150,000 alumni to receive both the UCI Medal and the Extraordinarious Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Yuen received his Bachelor of Science Degree in Electrical
Engineering from University of California, Irvine in 1974 with honors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PharmaCyte Biotech</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmaCyte Biotech is a clinical stage
biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation
technology known as &ldquo;Cell-in-a-Box<SUP>&reg;</SUP>.&rdquo; This technology will be used as a platform upon which therapies
for several types of cancer and diabetes are being developed. PharmaCyte&rsquo;s therapy for cancer involves encapsulating genetically
engineered human cells that convert an inactive chemotherapy drug into its active or &ldquo;cancer-killing&rdquo; form. These encapsulated
cells are implanted as close to the patient&rsquo;s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally
activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory
system to where the encapsulated cells have been implanted. When the ifosfamide flows through the encapsulated cells, they act
as a &ldquo;bio-artificial liver&rdquo; and activate the chemotherapy drug at the site of the cancer. This &ldquo;targeted chemotherapy&rdquo;
has proven effective and safe to use in past clinical trials and results in no treatment related side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to developing a novel therapy
for cancer, PharmaCyte is developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate
a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood
sugar in the human body. The encapsulation will be done using the Cell-in-a-Box<SUP>&reg;</SUP> technology. Once the encapsulated
cells are implanted in a diabetic patient they will function as a &ldquo;bio-artificial pancreas&rdquo; for purposes of insulin
production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Safe Harbor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking
statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words
&quot;expects,&quot; &quot;anticipates,&quot; &quot;believes,&quot; &quot;intends,&quot; &quot;estimates,&quot; &quot;plans,&quot;
&quot;will,&quot; &quot;outlook&quot; and similar expressions. Forward-looking statements are based on management's current plans,
estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking
statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors,
many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and
Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">More information
about PharmaCyte Biotech can be found at <FONT STYLE="color: blue">www.PharmaCyte.com<U>.</U></FONT> Information may also be obtained
by contacting PharmaCyte&rsquo;s Investor Relations Department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmaCyte Biotech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telephone: 917.595.2856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: <FONT STYLE="color: blue">Info@PharmaCyte.com</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !A 74# 2(  A$! Q$!_\0
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MN^U6^,9SY@Q_.I;:ZCO(1)%(DJ'HR,&!_$5D:DE%5Y]5MK6<127$$<A&0C2
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MM;[Q8Z<HJ+AO>Y^J\4JS1JZ$,K ,I'0@TEQ<):6[RR,$CC4N['HH'))KP?\
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MF^&%WHF(?M#30W%N\HXBDCD5MWUP"/QKM:*X(R<7='H22DK,^3/V\OV2YI?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
